New study pits rybelsus against other diabetes pills in Real-World setting

NCT ID NCT05035082

Completed Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 11, 2026 · Updated 4 times

Summary

This completed study compared the effectiveness of once-daily oral semaglutide (Rybelsus) to other oral diabetes medications in 1020 adults with type 2 diabetes who were already taking metformin. Participants were randomly assigned to receive either Rybelsus or another diabetes pill, and their blood sugar control was tracked over about one year. The goal was to see which approach worked better in real-world healthcare settings.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide (Rybelsus)
What this could lead to: If successful, this study could show that oral semaglutide is more effective than other oral diabetes medications at lowering blood sugar when added to metformin.
What could go wrong: This is a completed Phase 4 trial, so results are already in. However, real-world effectiveness may vary, and the study does not test long-term outcomes like heart health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2

Contacts and locations

Locations

AnMed Health IMA

Anderson, South Carolina, 29621, United States
Baylor Scott & White Res Inst

Dallas, Texas, 75246, United States
Central Ohio Clinical Research LLC

Columbus, Ohio, 43213, United States
Chrysalis Clinical Research

St. George, Utah, 84790, United States
Clinical Research of Gastonia

Gastonia, North Carolina, 28054, United States
DC Research Works

Marietta, Georgia, 30060, United States
DCT-Stone Oak

San Antonio, Texas, 78258, United States
Diab & Endo Assoc of Stark Co

Canton, Ohio, 44718, United States
Endeavor Health

Skokie, Illinois, 60077, United States
FDRC

Costa Mesa, California, 92627, United States
Hill Country Medical Associates

New Braunfels, Texas, 78130, United States
Jefferson Endocrinology Assocs

Philadelphia, Pennsylvania, 19107-6810, United States
Kernodle Clin Dpt-Pvt Diagnost

Burlington, North Carolina, 27215, United States
Macoupin Research Group

Gillespie, Illinois, 62033, United States
OnSite Clinical Solutions, LLC_Charlotte

Charlotte, North Carolina, 28277, United States
Preferred Primary Care Physicians_Pittsburgh

Pittsburgh, Pennsylvania, 15236, United States
Raincross Medical Group

Riverside, California, 92506, United States
Reyes Clinical Research, Inc

Miami, Florida, 33175, United States
Scripps Whittier Diabetes Inst

La Jolla, California, 92037, United States
Stewart Medical Group

Alhambra, California, 91801, United States
Tristar Clin Investigations, PC

Philadelphia, Pennsylvania, 19114, United States
UnityPoint Health-Diabetes Care Center

Peoria, Illinois, 61603, United States
Urban Family Practice Assoc

Marietta, Georgia, 30067, United States
Valley Weight Loss Clinic

Fargo, North Dakota, 58104, United States
WakeMed Garner Hlthplx

Garner, North Carolina, 27529, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.